13 July 2026: UK Research and Innovation (UKRI) has launched a new five-year strategy aimed at strengthening the UK's research and innovation ecosystem, with a major focus on artificial intelligence, life sciences, quantum technologies, and clean energy. Supported by the government's record £38.6 billion investment in research and development, the roadmap is designed to accelerate scientific discovery, boost economic growth, and reinforce the UK's position as a global innovation leader.

The strategy outlines UKRI's commitment to supporting cutting-edge research while helping innovative businesses grow and commercialise breakthrough technologies. A key objective is to maximise the impact of public investment by attracting private capital, with the organisation targeting at least £3 of private investment for every £1 of public funding.

For the biotechnology and healthcare sectors, the roadmap signals continued investment in AI-driven research, advanced computing, and translational science. These priorities are expected to accelerate the development of next-generation therapies, improve healthcare innovation, and strengthen collaboration between academia, industry, and government.

Over the next five years, UKRI plans to support more than 20,000 doctoral researchers, expand regional research and innovation clusters, and deliver major national initiatives, including the UK's new AI Strategy and the rollout of the national supercomputing service in Edinburgh. The organisation will also modernise its own operations by adopting digital technologies and AI-powered processes to reduce administrative burdens and improve funding efficiency.

Alongside investments in strategic technologies, UKRI reaffirmed its commitment to curiosity-driven research, recognising that many of today's transformative medical and scientific breakthroughs originate from fundamental discovery science. The strategy aims to balance long-term scientific exploration with targeted investment in areas that support the UK's industrial and economic priorities.

The roadmap has been welcomed by leaders across the UK's research community, who see it as an important step towards strengthening collaboration between universities, industry, and government while creating an environment where innovative ideas can progress more rapidly from laboratory research to commercial and clinical applications.

For the biotechnology sector, the strategy reinforces the UK's ambition to remain at the forefront of global life sciences innovation. Continued investment in AI, advanced research infrastructure, and talent development is expected to create new opportunities for biotech companies, researchers, and healthcare innovators, supporting the development of breakthrough technologies that can improve patient outcomes and drive sustainable economic growth.